MedTrace Logo

Introducing a Telemedicine Strategy to Deliver Cervical Cancer Screening Results in El Salvador

NCT07482306 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1103

Last updated 2026-08-03

No results posted yet for this study

Summary

Telemedicine, the use of telecommunication technologies to provide healthcare services remotely, has grown exponentially in the last decade. The COVID-19 pandemic highlighted the potential of these approaches as routine clinical interactions transitioned from in-person to virtual modalities around the world. While some telemedicine applications are only feasible in high-resource settings, other types have been shown to be effective in low and middle-income countries (LMICs). Interventions that utilize mobile devices such as cellular phones and digital tablets, collectively known as mobile health or mHealth, may enable greater patient access to some services and reduce the strain on resource-limited health systems. Here we describe the use of an mHealth strategy to facilitate delivery of cervical cancer screening results in El Salvador.

Conditions

  • Cervical Cancer Screening

Interventions

BEHAVIORAL

Telemedicine

Women receive their screening results via SMS message instead of in person

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • The Cleveland Clinic

    lead OTHER

Principal Investigators

  • Miriam Cremer, MD · The Cleveland Clinic

Study Design

Allocation
NON_RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
59 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-31
Primary Completion
2024-01-31
Completion
2024-01-31

Countries

  • El Salvador

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07482306 on ClinicalTrials.gov